SCHEMBL19124348

SCHEMBL19124348

NC(=O)CC[CH]c1cccc(Br)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP9X Q93008 2/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CTH P32929 3/20 0.35
STAT3 P40763 1/20 0.34
UCHL1 P09936 1/20 0.33
USP5 P45974 1/20 0.33
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
TBXAS1 P24557 1/20 0.31
GRM5 P41594 1/20 0.31
LMNA P02545 1/20 0.30
CTSA P10619 1/20 0.30
TERT O14746 1/20 0.30
NR4A2 P43354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3465374 0.83 USP9X (0.39) USP9XALDH1A1HPGDCTHSTAT3
SCHEMBL13358884 0.77 P2RX7 (0.47)
SCHEMBL3465384 0.75 USP9X (0.40) USP9XALDH1A1HPGDCTHSTAT3
SCHEMBL15618374 0.73 NPC1 (0.45) ALDH1A1HPGDTBXAS1LMNA
SCHEMBL27827262 0.71 CTH (0.41) USP9XALDH1A1HPGDCTHSTAT3
SCHEMBL17440498 0.70 KCNH2 (0.38) ALDH1A1HPGDTBXAS1LMNANR4A2
SCHEMBL2401094 0.70 ALDH1A1 (0.53) ALDH1A1LMNA
SCHEMBL3466287 0.69 FPR2 (0.36) ALDH1A1TBXAS1
SCHEMBL9232447 0.68 TBXAS1 (0.45) USP9XALDH1A1HPGDTBXAS1LMNA
SCHEMBL9232445 0.68 TBXAS1 (0.45) USP9XALDH1A1HPGDTBXAS1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577367-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2020-03-03 US disclosed
US-20190248787-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2019-08-15 US disclosed
US-10246456-B2 IRAK4 inhibiting agents BIOGEN MA INC. (US) 2019-04-02 US disclosed
US-20170204093-A1 IRAK4 INHIBITING AGENTS BIOGEN MA INC. 2017-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246456-B2 IRAK4 inhibiting agents IRAK4, IRAK1, IRAK2 USP9X 1089/4885ALDH1A1 3021/4885HPGD 4658/4885
US-20170204093-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 USP9X 1089/4885ALDH1A1 3021/4885HPGD 4658/4885
US-20190248787-A1 IRAK4 INHIBITING AGENTS IRAK4, IRAK1, IRAK2 USP9X 1017/4885ALDH1A1 3110/4885HPGD 4619/4885
US-10577367-B2 IRAK4 inhibiting agents IRAK4, IRAK1, IRAK2 USP9X 1017/4885ALDH1A1 3110/4885HPGD 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.